2026 Q2 - tulosraportti
29 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·20 t sittenLet the penny-stock traders keep doing their thing, that is not what this is about, the trading has nothing to do with the company, I bet they do not know what the company works with ):
·20 t sitten · MuokattuEvery time I top up on this! Then it plunges :( So going forward I have to top up half at a time 😂 Aren't any research results coming soon? What are we waiting for now?
I don't think any big things will happen before Q1-2027...., but I hope I'm wrong :). So it's probably just a matter of staying calm and it will go up eventually. I will try to buy some if it drops even further...., if not then I'll buy more around the turn of the month nov/dec I think :).
·23 t sittenHave dug a bit into the environment in Galway, where SIS-02 is being carried out. Have had important things highlighted. The most interesting is what academic and practical apparatus SoftOx has managed to mobilize around the study. If we only look at the company's own organization, I believe we significantly underestimate the execution capability. SIS-02 is part of COUNTERACT, a European development program funded through the European Defence Fund and supported by the Norwegian Ministry of Defence. Daniel O’Toole is scientific lead for sis02 and local Galway lead for COUNTERACT's !!! clinical work package. He is thus directly involved in the execution of the SoftOx study, not just a person the company has contact with. O’Toole has long experience in pulmonary research, 20 years, inhaled delivery and development from the laboratory and animal models towards clinical studies in humans. His field also includes medical countermeasures against chemical, biological, radiological and nuclear threats. Around SIS-02 there are also three established clinical units and an interdisciplinary team that knows the pitfalls in the academic, regulatory and economic. That is quite a different starting point than a small company having to build up all the expertise itself. A concrete connection is the collaboration between O’Toole, intensive care medicine professor John G. Laffey and Ronan MacLoughlin from Aerogen. They have published together on inhaled treatments, and in a 2023 animal study they used Aerogen Solo. Galway has also completed funded development projects with Aerogen and other industry partners. The significance is experience with the entire interplay between treatment, delivery technology and biological models, not just familiarity with a nebulizer. SoftOx stated in the Q3 report for 2024 that FFI had tested whether SIS was compatible with several commercial nebulizers, and that a main apparatus had been chosen for the upcoming study. Then the company wrote: <"This device will further be evaluated in a feasibility test for use in a military setting."> The chosen device was thus to be further evaluated for military use. Apparatus choice and military suitability were thus a concrete part of the described development path already then. The end goal is a product the soldier can carry and use in the field, in other words. Add FFI's apparatus testing and Bruce Montgomery's, seen as a legend in the field, with experience from the development of inhalation drugs up to approval, fda. Then you see several complementary parts of the development path: microbiology, delivery, preclinical research, clinical execution and drug development. COUNTERACT at the same time provides a concrete arena for collaboration with European defense and research actors. For me, this is a significant finding in itself. SoftOx does not need to own the entire development apparatus to gain access to the expertise. The results still have to be delivered, but the company sits in a far more competent nest than size and internal staffing alone would suggest. For me, this gives a significantly stronger picture of SoftOx's ability to execute the SIS development than I had previously, and O Toole's role in conteract is extremely interesting in itself. Not a buy or sell recommendation, for information purposes only. [Source for O’Toole's role and the execution environment](https://www.linkedin.com/pulse/summer-review-2026-university-of-galway-institute-for-kiuke/) · [Research collaboration with Aerogen](https://pmc.ncbi.nlm.nih.gov/articles/PMC10245544/)an impressive piece of work you have done here Mrodseth, well done, take a seat in Hilbert Group as well, it is possibly going to be listed on the US exchange, some predict a 40-fold increase from today's price:-)
·1 päivä sittenGood morning fellow softoxers... Anyone who has an overview of how many shares the following have left? Diches...? SixSis...? If anyone else larger has come in? Hoping for an exciting day! PS!! Do not forget the military part, something can also happen there! Feel free to follow discord where this is also brought to light!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
29 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·20 t sittenLet the penny-stock traders keep doing their thing, that is not what this is about, the trading has nothing to do with the company, I bet they do not know what the company works with ):
- ·20 t sitten · MuokattuEvery time I top up on this! Then it plunges :( So going forward I have to top up half at a time 😂 Aren't any research results coming soon? What are we waiting for now?I don't think any big things will happen before Q1-2027...., but I hope I'm wrong :). So it's probably just a matter of staying calm and it will go up eventually. I will try to buy some if it drops even further...., if not then I'll buy more around the turn of the month nov/dec I think :).
- ·23 t sittenHave dug a bit into the environment in Galway, where SIS-02 is being carried out. Have had important things highlighted. The most interesting is what academic and practical apparatus SoftOx has managed to mobilize around the study. If we only look at the company's own organization, I believe we significantly underestimate the execution capability. SIS-02 is part of COUNTERACT, a European development program funded through the European Defence Fund and supported by the Norwegian Ministry of Defence. Daniel O’Toole is scientific lead for sis02 and local Galway lead for COUNTERACT's !!! clinical work package. He is thus directly involved in the execution of the SoftOx study, not just a person the company has contact with. O’Toole has long experience in pulmonary research, 20 years, inhaled delivery and development from the laboratory and animal models towards clinical studies in humans. His field also includes medical countermeasures against chemical, biological, radiological and nuclear threats. Around SIS-02 there are also three established clinical units and an interdisciplinary team that knows the pitfalls in the academic, regulatory and economic. That is quite a different starting point than a small company having to build up all the expertise itself. A concrete connection is the collaboration between O’Toole, intensive care medicine professor John G. Laffey and Ronan MacLoughlin from Aerogen. They have published together on inhaled treatments, and in a 2023 animal study they used Aerogen Solo. Galway has also completed funded development projects with Aerogen and other industry partners. The significance is experience with the entire interplay between treatment, delivery technology and biological models, not just familiarity with a nebulizer. SoftOx stated in the Q3 report for 2024 that FFI had tested whether SIS was compatible with several commercial nebulizers, and that a main apparatus had been chosen for the upcoming study. Then the company wrote: <"This device will further be evaluated in a feasibility test for use in a military setting."> The chosen device was thus to be further evaluated for military use. Apparatus choice and military suitability were thus a concrete part of the described development path already then. The end goal is a product the soldier can carry and use in the field, in other words. Add FFI's apparatus testing and Bruce Montgomery's, seen as a legend in the field, with experience from the development of inhalation drugs up to approval, fda. Then you see several complementary parts of the development path: microbiology, delivery, preclinical research, clinical execution and drug development. COUNTERACT at the same time provides a concrete arena for collaboration with European defense and research actors. For me, this is a significant finding in itself. SoftOx does not need to own the entire development apparatus to gain access to the expertise. The results still have to be delivered, but the company sits in a far more competent nest than size and internal staffing alone would suggest. For me, this gives a significantly stronger picture of SoftOx's ability to execute the SIS development than I had previously, and O Toole's role in conteract is extremely interesting in itself. Not a buy or sell recommendation, for information purposes only. [Source for O’Toole's role and the execution environment](https://www.linkedin.com/pulse/summer-review-2026-university-of-galway-institute-for-kiuke/) · [Research collaboration with Aerogen](https://pmc.ncbi.nlm.nih.gov/articles/PMC10245544/)an impressive piece of work you have done here Mrodseth, well done, take a seat in Hilbert Group as well, it is possibly going to be listed on the US exchange, some predict a 40-fold increase from today's price:-)
- ·1 päivä sittenGood morning fellow softoxers... Anyone who has an overview of how many shares the following have left? Diches...? SixSis...? If anyone else larger has come in? Hoping for an exciting day! PS!! Do not forget the military part, something can also happen there! Feel free to follow discord where this is also brought to light!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
29 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·20 t sittenLet the penny-stock traders keep doing their thing, that is not what this is about, the trading has nothing to do with the company, I bet they do not know what the company works with ):
- ·20 t sitten · MuokattuEvery time I top up on this! Then it plunges :( So going forward I have to top up half at a time 😂 Aren't any research results coming soon? What are we waiting for now?I don't think any big things will happen before Q1-2027...., but I hope I'm wrong :). So it's probably just a matter of staying calm and it will go up eventually. I will try to buy some if it drops even further...., if not then I'll buy more around the turn of the month nov/dec I think :).
- ·23 t sittenHave dug a bit into the environment in Galway, where SIS-02 is being carried out. Have had important things highlighted. The most interesting is what academic and practical apparatus SoftOx has managed to mobilize around the study. If we only look at the company's own organization, I believe we significantly underestimate the execution capability. SIS-02 is part of COUNTERACT, a European development program funded through the European Defence Fund and supported by the Norwegian Ministry of Defence. Daniel O’Toole is scientific lead for sis02 and local Galway lead for COUNTERACT's !!! clinical work package. He is thus directly involved in the execution of the SoftOx study, not just a person the company has contact with. O’Toole has long experience in pulmonary research, 20 years, inhaled delivery and development from the laboratory and animal models towards clinical studies in humans. His field also includes medical countermeasures against chemical, biological, radiological and nuclear threats. Around SIS-02 there are also three established clinical units and an interdisciplinary team that knows the pitfalls in the academic, regulatory and economic. That is quite a different starting point than a small company having to build up all the expertise itself. A concrete connection is the collaboration between O’Toole, intensive care medicine professor John G. Laffey and Ronan MacLoughlin from Aerogen. They have published together on inhaled treatments, and in a 2023 animal study they used Aerogen Solo. Galway has also completed funded development projects with Aerogen and other industry partners. The significance is experience with the entire interplay between treatment, delivery technology and biological models, not just familiarity with a nebulizer. SoftOx stated in the Q3 report for 2024 that FFI had tested whether SIS was compatible with several commercial nebulizers, and that a main apparatus had been chosen for the upcoming study. Then the company wrote: <"This device will further be evaluated in a feasibility test for use in a military setting."> The chosen device was thus to be further evaluated for military use. Apparatus choice and military suitability were thus a concrete part of the described development path already then. The end goal is a product the soldier can carry and use in the field, in other words. Add FFI's apparatus testing and Bruce Montgomery's, seen as a legend in the field, with experience from the development of inhalation drugs up to approval, fda. Then you see several complementary parts of the development path: microbiology, delivery, preclinical research, clinical execution and drug development. COUNTERACT at the same time provides a concrete arena for collaboration with European defense and research actors. For me, this is a significant finding in itself. SoftOx does not need to own the entire development apparatus to gain access to the expertise. The results still have to be delivered, but the company sits in a far more competent nest than size and internal staffing alone would suggest. For me, this gives a significantly stronger picture of SoftOx's ability to execute the SIS development than I had previously, and O Toole's role in conteract is extremely interesting in itself. Not a buy or sell recommendation, for information purposes only. [Source for O’Toole's role and the execution environment](https://www.linkedin.com/pulse/summer-review-2026-university-of-galway-institute-for-kiuke/) · [Research collaboration with Aerogen](https://pmc.ncbi.nlm.nih.gov/articles/PMC10245544/)an impressive piece of work you have done here Mrodseth, well done, take a seat in Hilbert Group as well, it is possibly going to be listed on the US exchange, some predict a 40-fold increase from today's price:-)
- ·1 päivä sittenGood morning fellow softoxers... Anyone who has an overview of how many shares the following have left? Diches...? SixSis...? If anyone else larger has come in? Hoping for an exciting day! PS!! Do not forget the military part, something can also happen there! Feel free to follow discord where this is also brought to light!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt